Patented technology for the production of full-length, correctly folded and functional proteins
Identify all autoantigens and antigens that make up the Autoproteome*
(*) Totality of all possible autoantigens and neoantigens representing a given disease and its sub-types
Quantify autoantibodies using a pin-prick of blood
Autoantigen discovery database
Bespoke content and project design services
Checkpoint Inhibitor Melanoma Trial
Study Design:
Metastatic melanoma, BRAF mutant patients, treated with experimental checkpoint inhibitor drugs.
Results:
Stratified patients into 3 cohorts (responsive, non-responsive, toxic).
Systemic Lupus Erythematosus (SLE)
Study Design:
Identification of novel autoantibodies in SLE and stratification of subgroups of SLE individuals.
Results:
4 SLE subgroups were categorised based on hierarchical clustering and principal component analysis (PCA) with known autoantigens such as TROVE2 (Ro60) and SSB (La) forming a single cluster and novel TGF-β signalling (SMAD2 and SMAD5) and TLR signalling (My88) autoantigens forming another cluster.
DNA-Protein Interaction Study
Study Design:
p53 microarray printed onto a neutravidin-derivatised dextran hydrogel surface probed with Cy3-labelled GADD45 duplex oligo
Results:
Quantitative parallel thermodynamic analysis revealed previously unknown functional effects of mutation on p53 protein-DNA interaction
Differential DNA binding activity of p53 mutant proteins
Quantitative analysis unravels mechanistic differences between ‘loss of function’ mutations
Colorectal Cancer
Study Design:
Results:
Breakdown of Selected/Identified Antigens